Dr. Lal Path Labs Ltd. has submitted to the Exchange, the financial results for the period ended March 31, 2026.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Smallcap 250 and 2.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs reported FY26 revenue of INR 27,629 million (up 12.25% from INR 24,614 million in FY25) and PAT of INR 5,098 million (up 3.57% from INR 4,922 million). Q4 FY26 standalone revenue was INR 7,027 million with PAT of INR 1,322 million. An exceptional item of INR 301 million was recorded for the impact of new Labour Codes on gratuity and leave liabilities. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated results. The Board recommended a final dividend of INR 4 per share (total FY26 dividend INR 20.5 per share), approved acquisition of Shahbazkers Diagnostic Centre as a wholly-owned subsidiary, and incorporation of a new subsidiary in Dubai. EPS figures for FY25 were restated due to the 1:1 bonus share issuance approved in December 2025.
Revenue growth of 12.25% and PAT growth of 3.57% reflect steady performance, though below high-growth thresholds. The clean audit opinion and regular dividend payouts are positive signals for shareholders. The expansion through acquisition and international subsidiary reflects strategic growth focus.